Journal of Clinical Oncology
Articles in this Issue
Effect of caprine herpes virus-1 (CpHV-1) on cell viability and chemosensitivity in breast cancer cells.
e13044 Background: Oncolytic viruses (OVs) are gaining recognition as therapeutic agents in oncology, functioning both as enhancers of established treatme...
Regulation of tumor-associated fibroblasts by TACSTD2 in esophageal squamous cell carcinoma and its potential role in immunotherapy resistance.
e16045 Background: Esophageal squamous cell carcinoma (ESCC) has high global incidence and mortality, with poor prognosis due to late diagnosis and limite...
A phase 1b study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC.
TPS2696 Background: For resectable stage II/III non-small cell lung cancer (NSCLC), neoadjuvant chemoimmunotherapy has become standard of care. Patients w...
Trends and disparities in end-of-life care among patients with pancreatic cancer.
e16389 Background: Pancreatic cancer is one of the most lethal cancers in the United States (U.S.), with a five-year survival rate of only 12% due to late...
A phase 1b dose escalation study of AV-380 (anti-GDF15 monoclonal antibody) in combination with standard-of-care therapy in cancer patients with cachexia.
TPS12142 Background: Cachexia is a complex and common cancer comorbidity associated with a high risk of death. Despite its significant impact, no FDA-appr...
PCT1:CO-STIM TCR T-cells to overcome the hostile tumor micro-environment and target triple-negative breast cancer.
2590 Background: Adoptive T-cell therapy has demonstrated impressive efficacy in hematoligical cancers but the solid tumor micro-environment presents a un...
Recruitment strategies and enrollment for a virtually supervised exercise intervention for Hispanic/Latinx breast cancer survivors.
10601 Background: Hispanic and/or Latinx cancer survivors remain underrepresented in clinical trials, particularly in exercise oncology and energy balance...
Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with <i>KRAS</i> G12C-mutant advanced NSCLC: Update from the LOXO-RAS-20001 trial.
8519 Background: Olomorasib, a potent, highly selective second-generation KRAS G12C inhibitor has demonstrated promising activity and a favorable safety p...
Advancing prostate cancer local recurrence detection: An analysis of optimal imaging modalities.
e17146 Background: Prostate-specific membrane antigen positron emission tomography-computed tomography (PSMA/PET CT) has become the gold standard for stag...
Outcomes of KRAS G12C inhibitors in metastatic pancreatic cancer: A systematic review and meta-analysis.
e16206 Background: Pancreatic cancer remains one of the most challenging malignancies to treat, marked by a 5-year survival rate as low as 5%. The KRAS G1...
Evaluating the real-world impact of atezolizumab and bevacizumab combination in unresectable hepatocellular carcinoma: A south Indian experience.
e16241 Background: The combination of atezolizumab and bevacizumab emerged as first-line systemic therapy in unresectable hepatocellular Carcinoma (uHCC),...
Communication of uncertainties about recent cancer drugs in large language models.
11026 Background: Increasingly more people use large language models (LLMs) to find information about medical treatments. However, there are notable conce...
Utilizing circulating tumor DNA methylation levels to predict pathological and radiological response in hepatocellular carcinoma patients undergoing neoadjuvant and systemic therapy.
e16323 Background: Systemic therapy of hepatocellular carcinoma (HCC) faces several challenges, including tumor heterogeneity and drug resistance. Previou...
Real world risk-stratified clinical pathways for cancer care management.
e13864 Background: Individuals diagnosed with metastatic and advanced cancers are living substantially longer. This population has prognostic uncertainty,...
Race-specific survival prediction models for de novo metastatic breast cancer using machine learning.
e13116 Background: Breast cancer is the most common malignancy among women and a major cause of cancer death. About 5-10% of breast cancer patients are in...
Importance of bulky lymph node involvement in locally advanced anal cancer.
e15500 Background: Anal squamous carcinoma accounts for 0.1% of global cancer cases, with rising incidence and mortality trends in the last decade. We wan...
Response to induction chemotherapy and identification of tumor heterogeneity through a comprehensive multi-omics profiling of HPV-associated oropharyngeal squamous cell carcinoma.
e18053 Background: The response of neoadjuvant chemotherapy (NAC) can guide personalized treatment de-intensification in HPV-associated oropharyngeal squa...
Effect of biopsy requirement on patient enrollment to phase I trials in cancer.
3154 Background: The need for safer and more effective drugs for patients with cancer is a constant unmet need. Given their narrow therapeutic index, dete...
Artificial intelligence based music therapy intervention in cancer patients undergoing chemotherapy in oncology day care (MUSICC).
1578 Background: Studies on the role of music therapy for improving the quality of life of cancer patients are scarce. Artificial intelligence (AI) is bei...
Neoadjuvant serplulimab with concurrent chemoradiotherapy in resectable esophagogastric junction adenocarcinoma: Phase 2 updated results.
2612 Background: This study evaluated the efficacy and safety of neoadjuvant Serplulimab combined with concurrent chemoradiotherapy for locally advanced r...
Improving minimal residual disease detection: A tumor-informed whole-genome approach.
e15089 Background: Minimal Residual Disease (MRD) detection is rapidly becoming an effective tool for cancer management, enabling early relapse identifica...
Rechallenge with first-generation RET inhibitors in <i>RET</i> -rearranged NSCLC pre-treated with selpercatinib or pralsetinib: Results from the RET MAP registry.
8646 Background: RET fusions occur in 1-2% of patients with advanced non-small cell lung cancer (aNSCLC). First-generation RET inhibitors (RET...
HIPEC combined with camrelizumab, paclitaxel and S-1 for conversion therapy in patients with advanced gastric cancer with peritoneal metastasis: A prospective phase II clinical study.
e16017 Background: This phase II study aimed to evaluate the efficacy and safety of systemic chemoimmunotherapy and hyperthermic intraperitoneal chemother...
MSI-H colon cancer: Can we utilize a watch and wait approach?
e15652 Background: Recent studies shown that neoadjuvant Immune checkpoint inhibitor (ICI) followed by watch and wait (WW) with salvage surgery at recurre...
Knowledge, attitudes and practices of breast cancer screening among women in rural communities in FCT, Nigeria: A cross-sectional study.
e13515 Background: Breast Cancer (BC) is the most frequently diagnosed cancer, and the commonest cause of cancer deaths among women in Nigeria. BC inciden...